Table of Contents Author Guidelines Submit a Manuscript
Journal of Biomedicine and Biotechnology
Volume 2011, Article ID 873874, 8 pages
http://dx.doi.org/10.1155/2011/873874
Research Article

Expression of Recombinant Human Coagulation Factor VII by the Lizard Leishmania Expression System

1Department of Biology, Science and Research Branch, Islamic Azad University, Tehran, Iran
2Cellular and Molecular Biology Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
3Biotechnology Department, Pasteur Institute, Tehran, Iran
4Department of Hematology, Faculty of Paramedical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran
5Biotechnology Department, Faculty of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Received 19 March 2011; Revised 28 April 2011; Accepted 17 June 2011

Academic Editor: Michael Kalafatis

Copyright © 2011 Sina Mirzaahmadi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. B. Osterud and S. I. Rapaport, “Activation of factor IX by the reaction product of tissue factor and factor VII: additional pathway for initiating blood coagulation,” Proceedings of the National Academy of Sciences of the United States of America, vol. 74, no. 12, pp. 5260–5264, 1977. View at Google Scholar · View at Scopus
  2. F. S. Hagen, C. L. Gray, and P. O'Hara, “Characterization of a cDNA coding for human factor VII,” Proceedings of the National Academy of Sciences of the United States of America, vol. 83, no. 8, pp. 2412–2416, 1986. View at Google Scholar · View at Scopus
  3. A. C. W. Pike, A. M. Brzozowski, S. M. Roberts, O. H. Olsen, and E. Persson, “Structure of human factor VIIa and its implications for the triggering of blood coagulation,” Proceedings of the National Academy of Sciences of the United States of America, vol. 96, no. 16, pp. 8925–8930, 1999. View at Publisher · View at Google Scholar · View at Scopus
  4. F. Hagen, M. Murray et al., “Expression of factor VII activity in mammalian cells,” U.S. Patent, no. 4, pp. 784-950, 1988.
  5. U. Hedner and C. A. Lee, “First 20 years with recombinant FVIIa (NovoSeven),” Haemophilia, vol. 17, no. 1, pp. e172–e182, 2011. View at Publisher · View at Google Scholar · View at PubMed
  6. R. B. Weiskopf, “Recombinant-activated coagulation factor VIIa (NovoSeven): current development,” Vox Sanguinis, vol. 92, no. 4, pp. 281–288, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  7. A. Mayo, M. Misgav, Y. Kluger et al., “Recombinant activated factor VII (NovoSeven): addition to replacement therapy in acute, uncontrolled and life-threatening bleeding,” Vox Sanguinis, vol. 87, no. 1, pp. 34–40, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  8. M. Levi, M. Peters, and H. R. Büller, “Efficacy and safety of recombinant factor VIIa for treatment of severe bleeding: a systematic review,” Critical Care Medicine, vol. 33, no. 4, pp. 883–890, 2005. View at Publisher · View at Google Scholar · View at Scopus
  9. M. Levi, J. H. Levy, H. F. Andersen, and D. Truloff, “Safety of recombinant activated factor VII in randomized clinical trials,” New England Journal of Medicine, vol. 363, no. 19, pp. 1791–1800, 2010. View at Publisher · View at Google Scholar · View at PubMed
  10. N. Masroori, R. Halabian, M. Mohammadipour et al., “High-level expression of functional recombinant human coagulation factor VII in insect cells,” Biotechnology Letters, vol. 32, no. 6, pp. 803–809, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  11. R. Halabian, M. H. Roudkenar, N. S. Esmaeili, N. Masroori, A. M. Roushandeh, and A. J. Najafabadi, “Establishment of a cell line expressing recombinant factor VII and its subsequent conversion to active form FVIIa through hepsin by genetic engineering method,” Vox Sanguinis, vol. 96, no. 4, pp. 309–315, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  12. R. Sodoyer, “Expression systems for the production of recombinant pharmaceuticals,” BioDrugs, vol. 18, no. 1, pp. 51–62, 2004. View at Publisher · View at Google Scholar · View at Scopus
  13. F. Hesse and R. Wagner, “Developments and improvements in the manufacturing of human therapeutics with mammalian cell cultures,” Trends in Biotechnology, vol. 18, no. 4, pp. 173–180, 2000. View at Publisher · View at Google Scholar · View at Scopus
  14. R. Breitling, S. Klingner, N. Callewaert et al., “Non-pathogenic trypanosomatid protozoa as a platform for protein research and production,” Protein Expression and Purification, vol. 25, no. 2, pp. 209–218, 2002. View at Publisher · View at Google Scholar · View at Scopus
  15. C. Fritsche, M. Sitz, N. Weiland, R. Breitling, and H. D. Pohl, “Characterization of the growth behavior of Leishmania tarentolae—a new expression system for recombinant proteins,” Journal of Basic Microbiology, vol. 47, no. 5, pp. 384–393, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  16. C. Fritsche, M. Sitz, M. Wolf, and H. D. Pohl, “Development of a defined medium for heterologous expression in Leishmania tarentolae,” Journal of Basic Microbiology, vol. 48, no. 6, pp. 488–495, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  17. B. Kazemi, G. Tahvildar, S. R. H. Feshareki, and E. E. Javadian, “Isolation a lizard Leishmania promastigote from natural host in Iran,” Journal of Biological Sciences, vol. 4, no. 5, pp. 620–623, 2004. View at Google Scholar
  18. S. Koizume, M. S. Jin, E. Miyagi et al., “Activation of cancer cell migration and invasion by ectopic synthesis of coagulation factor VII,” Cancer Research, vol. 66, no. 19, pp. 9453–9460, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  19. W. Gaastra and K. Hansen, “Ligation of DNA with t4 DNA ligase,” Methods in Molecular Biology, vol. 2, pp. 225–230, 1985. View at Google Scholar
  20. D. Hanahan, “Studies on transformation of Escherichia coli with plasmids,” Journal of Molecular Biology, vol. 166, no. 4, pp. 557–580, 1983. View at Google Scholar · View at Scopus
  21. K. A. Robinson and S. M. Beverley, “Improvements in transfection efficiency and tests of RNA interference (RNAi) approaches in the protozoan parasite Leishmania,” Molecular and Biochemical Parasitology, vol. 128, no. 2, pp. 217–228, 2003. View at Publisher · View at Google Scholar · View at Scopus
  22. M. Soleimani, F. Mahboudi, N. Davoudi et al., “Expression of human tissue plasminogen activator in the trypanosomatid protozoan Leishmania tarentolae,” Biotechnology and Applied Biochemistry, vol. 48, no. 1, pp. 55–61, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  23. H. P. Phan, M. Sugino, and T. Niimi, “The production of recombinant human laminin-332 in a Leishmania tarentolae expression system,” Protein Expression and Purification, vol. 68, no. 1, pp. 79–84, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  24. R. Toso, M. Pinotti, K. A. High, E. S. Pollak, and F. Bernardi, “A frequent human coagulation Factor VII mutation (A294V, c152) in loop 140s affects the interaction with activators, tissue factor and substrates,” Biochemical Journal, vol. 363, no. 2, pp. 411–416, 2002. View at Publisher · View at Google Scholar · View at Scopus
  25. E. Handman, “Cell biology of Leishmania,” Advances in Parasitology, vol. 44, pp. 1–39, 1999. View at Google Scholar
  26. S. M. Ruiz, S. Sridhara, M. A. Blajchman, and B. J. Clarke, “Expression and purification of recombinant rabbit factor VII,” Thrombosis Research, vol. 98, no. 2, pp. 203–211, 2000. View at Publisher · View at Google Scholar · View at Scopus
  27. N. Wajih, J. Owen, and R. Wallin, “Enhanced functional recombinant factor VII production by HEK 293 cells stably transfected with VKORC1 where the gamma-carboxylase inhibitor calumenin is stably suppressed by shRNA transfection,” Thrombosis Research, vol. 122, no. 3, pp. 405–410, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  28. A. J. Parodi, “N-Glycosylation in trypanosomatid protozoa,” Glycobiology, vol. 3, no. 3, pp. 193–199, 1993. View at Google Scholar
  29. G. Bolt, C. Kristensen, and T. D. Steenstrup, “Posttranslational N-glycosylation takes place during the normal processing of human coagulation factor VII,” Glycobiology, vol. 15, no. 5, pp. 541–547, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  30. P. Margaritis, V. R. Arruda, M. Aljamali, R. M. Camire, A. Schlachterman, and K. A. High, “Novel therapeutic approach for hemophilia using gene delivery of an engineered secreted activated Factor VII,” Journal of Clinical Investigation, vol. 113, no. 7, pp. 1025–1031, 2004. View at Publisher · View at Google Scholar · View at Scopus